Trial reportWorld journal of gastroenterology2009
Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori.
Trial report in World journal of gastroenterology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Safety of furazolidone-containing regimen inBMJ open · 2020Pooled it
- Furazolidone-based therapies for Helicobacter pylori infection: a pooled-data analysis.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationPooled it
- Low dose furazolidone for eradication of H- pylori instead of clarithromycin: a clinical trial.Global journal of health science · 2014Trial
- Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection.World journal of gastroenterology · 2014Trial
- Efficacy and safety of tetracycline vs. amoxicillin in furazolidone-based rescue therapy forAnnals of medicine · 2025Article
- Anti-Helicobacter pylori Infection Treatment and Pulmonary Hypersensitivity: Case Series and Review of the Literature.The clinical respiratory journal · 2024Review
- Multiple Bismuth Quadruple Therapy Containing Tetracyclines Combined with Other Antibiotics andJournal of clinical medicine · 2022Review
- Risk factors of furazolidone-associated fever.PloS one · 2022Article
- Rescue Therapy with Furazolidone in Patients with at Least Five Eradication Treatment Failures and Multi-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Comparing the Effect of Two Low-dose and High-dose Four-drug Regimens of Furazolidone in EradicatingMiddle East journal of digestive diseases · 2021Article
- Susceptibility-guided bismuth quadruple therapies for resistantPrecision clinical medicine · 2020Article
- Five alternative Helicobacter pylori antibiotics to counter high levofloxacin and metronidazole resistance in the Dominican Republic.PloS one · 2019Article
- Outcomes of furazolidone- and amoxicillin-based quadruple therapy forWorld journal of gastroenterology · 2018Article
- Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies.Expert review of anti-infective therapy · 2018Review
- Comparison of quadruple and triple Furazolidone containing regimens on eradication of helicobacter pylori.Medical journal of the Islamic Republic of Iran · 2015Article
- Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China.European journal of gastroenterology & hepatology · 2013Review
- In vitro antibacterial activity of acyl-lysyl oligomers against Helicobacter pylori.Antimicrobial agents and chemotherapy · 2009Article
- Treatment with compound Lactobacillus acidophilus followed by a tetracycline- and furazolidone-containing quadruple regimen as a rescue therapy for Helicobacter pylori infection.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo compare the efficacy and side effect profiles of three furazolidone and amoxicillin-based quadruple rescue therapies for the eradication of Helicobacter pylori (H pylori).
methodsPatients who failed in the H pylori eradication therapy for at least one course were randomly allocated into three groups. Group A received rebaprazole 10 mg + amoxicillin 1 g + furazolidone 100 mg, and bismuth subcitrate 220 mg, twice daily for 1 wk; group B received the same regimen of group A but for 2 wk; and group C received the same regimen of group B, but furazolidone was replaced by furazolidone 100 mg three times daily. To record the side effect profiles at the end of the treatment, H pylori eradication was assessed with (13)C-urea breath test 4 wk after therapy.
resultsSixty patients were enrolled including 28 males, and 20 patients in each group. The average age of the patients was 49.2 years, ranging from 18 to 84 years. H pylori eradication rates with per-protocol analysis were 82%, 89% and 90% in the three groups, respectively. Side effects were found in 11 patients, including mild dizziness, nausea, diarrhea and increased bowel movement. None of the 11 patients needed treatment for their side effects.
conclusionOne- or two-week furazolidone and amoxicillin-based quadruple rescue therapy with a low dose furazolidone (100 mg bid) for the eradication of H pylori is effective. Extending the antibiotic course to 14 d could improve the eradication rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.